[
  {
    "ts": null,
    "headline": "The GLP-1 Saga Continues, And How",
    "summary": "The GLP-1 Saga Continues, And How",
    "url": "https://finnhub.io/api/news?id=204931e369efb88a8dd36991182948f33ff0cf9af25198dbd417b8f9328e27c1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746133500,
      "headline": "The GLP-1 Saga Continues, And How",
      "id": 134178628,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=204931e369efb88a8dd36991182948f33ff0cf9af25198dbd417b8f9328e27c1"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Index Rises After Strong Start to Big Tech Earnings",
    "summary": "The S&P 500 advanced 0.6% on Thursday, May 1, securing its eighth straight winning session as strong results from Microsoft and Meta helped boost tech stocks.",
    "url": "https://finnhub.io/api/news?id=527ab94a977f9ccbf53443ae576b93d08215b30404f2b26502224c0275405bad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746131348,
      "headline": "S&P 500 Gains and Losses Today: Index Rises After Strong Start to Big Tech Earnings",
      "id": 134184703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 advanced 0.6% on Thursday, May 1, securing its eighth straight winning session as strong results from Microsoft and Meta helped boost tech stocks.",
      "url": "https://finnhub.io/api/news?id=527ab94a977f9ccbf53443ae576b93d08215b30404f2b26502224c0275405bad"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates",
    "summary": "Eli Lilly Cuts Outlook, Shares Sink on Disappointing Profit",
    "url": "https://finnhub.io/api/news?id=d828ff5e2423123ffa2acae0675093833e5518e80d55ca699c2e1a3cf07f9e5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746128591,
      "headline": "Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates",
      "id": 134184704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Cuts Outlook, Shares Sink on Disappointing Profit",
      "url": "https://finnhub.io/api/news?id=d828ff5e2423123ffa2acae0675093833e5518e80d55ca699c2e1a3cf07f9e5a"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years?",
    "summary": "We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities […]",
    "url": "https://finnhub.io/api/news?id=2d76d6885b11032ded2b113969ae3dfb02af1b1cd8203a182944b83f00a73705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746126869,
      "headline": "Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years?",
      "id": 134184705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities […]",
      "url": "https://finnhub.io/api/news?id=2d76d6885b11032ded2b113969ae3dfb02af1b1cd8203a182944b83f00a73705"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Nosediving",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer qua",
    "url": "https://finnhub.io/api/news?id=3522c9043203133e08835ba29b9abeaf9c911f6819cac03bfbaf76e310378545",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746125103,
      "headline": "Why Eli Lilly (LLY) Stock Is Nosediving",
      "id": 134184706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer qua",
      "url": "https://finnhub.io/api/news?id=3522c9043203133e08835ba29b9abeaf9c911f6819cac03bfbaf76e310378545"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'",
    "summary": "Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.",
    "url": "https://finnhub.io/api/news?id=8181f963111e12c230e1e6281c49934ec8eafb69a57166845b72dc357eb8ab98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746124942,
      "headline": "Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'",
      "id": 134184707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.",
      "url": "https://finnhub.io/api/news?id=8181f963111e12c230e1e6281c49934ec8eafb69a57166845b72dc357eb8ab98"
    }
  },
  {
    "ts": null,
    "headline": "3 things we've learned from healthcare earnings",
    "summary": "Yahoo Finance Senior Health Reporter Anjalee Khemlani joins the Wealth team in breaking down the biggest themes she is seeing in the healthcare space from this earnings season, ranging from CVS Health's (CVS) earnings beat, trends in health insurance providers, rising medical costs, and the pricing on GLP-1 weight-loss drugs. Catch Anjalee's coverage of Eli Lilly's (LLY) stock reaction to its earnings print. Also, watch Yahoo Finance's interview with Oscar Health (OSCR) CEO Mark Bertolini from December 2024, where he characterized the healthcare system as having been \"broken for some time.\" To watch more expert insights and analysis on the latest market action, check out more Wealth here.",
    "url": "https://finnhub.io/api/news?id=8127865b5be6a61a9a94ea3e6034bccf792724ba2932afcf6cccdd30303fcfcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746122641,
      "headline": "3 things we've learned from healthcare earnings",
      "id": 134184708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Health Reporter Anjalee Khemlani joins the Wealth team in breaking down the biggest themes she is seeing in the healthcare space from this earnings season, ranging from CVS Health's (CVS) earnings beat, trends in health insurance providers, rising medical costs, and the pricing on GLP-1 weight-loss drugs. Catch Anjalee's coverage of Eli Lilly's (LLY) stock reaction to its earnings print. Also, watch Yahoo Finance's interview with Oscar Health (OSCR) CEO Mark Bertolini from December 2024, where he characterized the healthcare system as having been \"broken for some time.\" To watch more expert insights and analysis on the latest market action, check out more Wealth here.",
      "url": "https://finnhub.io/api/news?id=8127865b5be6a61a9a94ea3e6034bccf792724ba2932afcf6cccdd30303fcfcf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance",
    "summary": "Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net income that showcased strong year-over-year growth. Despite affirming its revenue guidance, the company's decision to lower EPS forecasts amidst IPR&D charges and investment losses saw shares decline. Albeit negatively impacted, the company's 9.20% price move aligns closely with overall market trends, evidenced by strong movements in major indices like the Dow Jones and...",
    "url": "https://finnhub.io/api/news?id=227cd1a98e013ebe557f3b5804e5134376077ad049e0f5a21d7baa49ace30458",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746122579,
      "headline": "Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance",
      "id": 134184709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net income that showcased strong year-over-year growth. Despite affirming its revenue guidance, the company's decision to lower EPS forecasts amidst IPR&D charges and investment losses saw shares decline. Albeit negatively impacted, the company's 9.20% price move aligns closely with overall market trends, evidenced by strong movements in major indices like the Dow Jones and...",
      "url": "https://finnhub.io/api/news?id=227cd1a98e013ebe557f3b5804e5134376077ad049e0f5a21d7baa49ace30458"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy",
    "summary": "Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.",
    "url": "https://finnhub.io/api/news?id=0142d10cfe7cd5695c6d466ca1328e5f60a9985a7e3cc19803ce29752ff615ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746121487,
      "headline": "Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy",
      "id": 134175948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.",
      "url": "https://finnhub.io/api/news?id=0142d10cfe7cd5695c6d466ca1328e5f60a9985a7e3cc19803ce29752ff615ab"
    }
  },
  {
    "ts": null,
    "headline": "Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health",
    "summary": "Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.  CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.  The formulary is maintained by CVS Health’s pharmacy benefits management business, which runs prescription drug coverage for millions of people.",
    "url": "https://finnhub.io/api/news?id=3a227ed953be34701ae75ad7fc94f66de4cf247f3fdc60c2924012f112c2e62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746118947,
      "headline": "Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health",
      "id": 134184711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.  CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.  The formulary is maintained by CVS Health’s pharmacy benefits management business, which runs prescription drug coverage for millions of people.",
      "url": "https://finnhub.io/api/news?id=3a227ed953be34701ae75ad7fc94f66de4cf247f3fdc60c2924012f112c2e62f"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Is Sinking Today",
    "summary": "Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings.  Shares of Eli Lilly (NYSE: LLY) are sliding on Thursday.  The pharmaceutical giant released earnings that disappointed investors despite strong sales growth.",
    "url": "https://finnhub.io/api/news?id=6b27389d42e8fe194edfdeb9d8524695a1e16ad07b9c18744a5e51e3ea05443d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746118193,
      "headline": "Why Eli Lilly Stock Is Sinking Today",
      "id": 134184712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings.  Shares of Eli Lilly (NYSE: LLY) are sliding on Thursday.  The pharmaceutical giant released earnings that disappointed investors despite strong sales growth.",
      "url": "https://finnhub.io/api/news?id=6b27389d42e8fe194edfdeb9d8524695a1e16ad07b9c18744a5e51e3ea05443d"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Microsoft, Eli Lilly, Kohl’s, Apple, Tesla, Meta, Qualcomm, CVS, and More",
    "summary": "These Stocks Moved the Most Today: Microsoft, Eli Lilly, Kohl’s, Apple, Tesla, Meta, Qualcomm, CVS, and More",
    "url": "https://finnhub.io/api/news?id=b3b3fab89dda9ed8cac4814a44ae01eb87c6da138792b4d9a33303cdcf2903c3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746116640,
      "headline": "These Stocks Moved the Most Today: Microsoft, Eli Lilly, Kohl’s, Apple, Tesla, Meta, Qualcomm, CVS, and More",
      "id": 134179060,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "These Stocks Moved the Most Today: Microsoft, Eli Lilly, Kohl’s, Apple, Tesla, Meta, Qualcomm, CVS, and More",
      "url": "https://finnhub.io/api/news?id=b3b3fab89dda9ed8cac4814a44ae01eb87c6da138792b4d9a33303cdcf2903c3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly slides, CVS earnings, Qualcomm's soft guidance",
    "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Eli Lilly's (LLY) declining share price despite topping first quarter earnings estimates, CVS Health's (CVS) recent earnings beat, and chipmaker Qualcomm (QCOM) issuing soft guidance over concerns around tariff pressures on smartphone demand. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=a12328428201f1242c9ae70dc4ec34b21d75beb8fecca5185b1b5838a72a3544",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746116375,
      "headline": "Eli Lilly slides, CVS earnings, Qualcomm's soft guidance",
      "id": 134173461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Eli Lilly's (LLY) declining share price despite topping first quarter earnings estimates, CVS Health's (CVS) recent earnings beat, and chipmaker Qualcomm (QCOM) issuing soft guidance over concerns around tariff pressures on smartphone demand. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=a12328428201f1242c9ae70dc4ec34b21d75beb8fecca5185b1b5838a72a3544"
    }
  },
  {
    "ts": null,
    "headline": "'Declare victory and move on': Eli Lilly CEO on Trump tariff threat",
    "summary": "Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.",
    "url": "https://finnhub.io/api/news?id=2c2e5044bc33af9ac4601d0d887ececd2ba1d64326a151e7e310a973c8dc0dd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746115606,
      "headline": "'Declare victory and move on': Eli Lilly CEO on Trump tariff threat",
      "id": 134173462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.",
      "url": "https://finnhub.io/api/news?id=2c2e5044bc33af9ac4601d0d887ececd2ba1d64326a151e7e310a973c8dc0dd0"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Microsoft, Meta Earnings Top Estimates; Eli Lilly Cuts Guidance Despite Strong Q1 Earnings",
    "summary": "All three major US stock indexes were up around midday trading Thursday after a couple of giant tech",
    "url": "https://finnhub.io/api/news?id=d5343b9ddf1dedc4e4c0c2a15887c5e11c5bc1dd1ff404a039e64b6444f0bd7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746114928,
      "headline": "Top Midday Stories: Microsoft, Meta Earnings Top Estimates; Eli Lilly Cuts Guidance Despite Strong Q1 Earnings",
      "id": 134173330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up around midday trading Thursday after a couple of giant tech",
      "url": "https://finnhub.io/api/news?id=d5343b9ddf1dedc4e4c0c2a15887c5e11c5bc1dd1ff404a039e64b6444f0bd7d"
    }
  },
  {
    "ts": null,
    "headline": "Why the Eli Lilly sell-off may be an 'overreaction'",
    "summary": "Eli Lilly (LLY) stock is sinking as investors react to concerns around GLP-1 drugs and industry dynamics. Red Brook Advisors managing partner Syed Husain joins Catalysts to discuss the market moves and explain why markets may be overreacting. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=bd29afc98a28b943f64f3e0c917c75d3052a06a8c931fd807d821d71e19e98a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746114631,
      "headline": "Why the Eli Lilly sell-off may be an 'overreaction'",
      "id": 134173465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) stock is sinking as investors react to concerns around GLP-1 drugs and industry dynamics. Red Brook Advisors managing partner Syed Husain joins Catalysts to discuss the market moves and explain why markets may be overreacting. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=bd29afc98a28b943f64f3e0c917c75d3052a06a8c931fd807d821d71e19e98a5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO Urges Trump to Ease Up on Tariffs, Extend 2017 Tax Cuts",
    "summary": "The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the broader pharmaceutical industry.  “We don’t believe tariffs are the right mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts Thursday.  “The announced tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said.",
    "url": "https://finnhub.io/api/news?id=c0f5d3c4bb192a59899812716a7cff9b8507b69f72da103447fc4945d792574a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746113599,
      "headline": "Eli Lilly CEO Urges Trump to Ease Up on Tariffs, Extend 2017 Tax Cuts",
      "id": 134173466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the broader pharmaceutical industry.  “We don’t believe tariffs are the right mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts Thursday.  “The announced tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said.",
      "url": "https://finnhub.io/api/news?id=c0f5d3c4bb192a59899812716a7cff9b8507b69f72da103447fc4945d792574a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript",
    "summary": "Eli Lilly and Company (NYSE:LLY) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ETCompany ParticipantsMike Czapar - Senior Vice President of Investor...",
    "url": "https://finnhub.io/api/news?id=694f1e4ff27a616e2354bcbd56c58bf43003690a5dff7f418dd5ed987fe14776",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746109029,
      "headline": "Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript",
      "id": 134176198,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ETCompany ParticipantsMike Czapar - Senior Vice President of Investor...",
      "url": "https://finnhub.io/api/news?id=694f1e4ff27a616e2354bcbd56c58bf43003690a5dff7f418dd5ed987fe14776"
    }
  },
  {
    "ts": null,
    "headline": "WHO set to back use of weight-loss drugs for adults globally",
    "summary": "STORY: The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time. A memo reviewed by Reuters Thursday says the UN...",
    "url": "https://finnhub.io/api/news?id=680f8220a6184a554e5ebba28094a1c8a534c643c82574b92618d50ea3e731f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746108784,
      "headline": "WHO set to back use of weight-loss drugs for adults globally",
      "id": 134176355,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "STORY: The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time. A memo reviewed by Reuters Thursday says the UN...",
      "url": "https://finnhub.io/api/news?id=680f8220a6184a554e5ebba28094a1c8a534c643c82574b92618d50ea3e731f1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Q1 win outweighed by Novo's CVS deal",
    "summary": "Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company lowering its full-year profit outlook. Investors are also reacting to a new deal between rival Novo Nordisk (NVO) and CVS (CVS) that could sideline Lilly's weight-loss drug Zepbound. Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to break down what's weighing on Eli Lilly's stock. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Editor's note: The headline was updated to better reflect what is moving the stock.",
    "url": "https://finnhub.io/api/news?id=2ea9a089c01e2e9a3173bba13cf38f8589367c57958268c8930950b16345a874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746108594,
      "headline": "Eli Lilly's Q1 win outweighed by Novo's CVS deal",
      "id": 134173467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company lowering its full-year profit outlook. Investors are also reacting to a new deal between rival Novo Nordisk (NVO) and CVS (CVS) that could sideline Lilly's weight-loss drug Zepbound. Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to break down what's weighing on Eli Lilly's stock. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Editor's note: The headline was updated to better reflect what is moving the stock.",
      "url": "https://finnhub.io/api/news?id=2ea9a089c01e2e9a3173bba13cf38f8589367c57958268c8930950b16345a874"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling.",
    "summary": "Eli Lilly’s  first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday morning, and the stock fell as  Novo Nordisk  ramped up efforts to claw back weight-loss market share.  Lilly’s weight-loss drug is the best available, and the company says it now has 53.3% of the U.S. market for incretin analogues, the class of drugs that includes its medicines Zepbound and Mounjaro.  Shares have been climbing, and the stock is up 18.9% over the past 12 months while shares of rival Novo are down 46.4% over the same period.",
    "url": "https://finnhub.io/api/news?id=ae355a17f9681046cc31193f38a726c0238eb81361dc5a868484ca4cc281f4f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746108420,
      "headline": "Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling.",
      "id": 134173468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s  first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday morning, and the stock fell as  Novo Nordisk  ramped up efforts to claw back weight-loss market share.  Lilly’s weight-loss drug is the best available, and the company says it now has 53.3% of the U.S. market for incretin analogues, the class of drugs that includes its medicines Zepbound and Mounjaro.  Shares have been climbing, and the stock is up 18.9% over the past 12 months while shares of rival Novo are down 46.4% over the same period.",
      "url": "https://finnhub.io/api/news?id=ae355a17f9681046cc31193f38a726c0238eb81361dc5a868484ca4cc281f4f7"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone",
    "summary": "Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.",
    "url": "https://finnhub.io/api/news?id=9a9f39f149eeba6f72e5aa8c7e4071119610becf1bc46b35da5f2499334b6d0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746107792,
      "headline": "CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone",
      "id": 134176013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157849824/image_2157849824.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.",
      "url": "https://finnhub.io/api/news?id=9a9f39f149eeba6f72e5aa8c7e4071119610becf1bc46b35da5f2499334b6d0c"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Big Macs Vs. Uncertainty",
    "summary": "McDonald's U.S. comp sales decline is the largest since 2020, due to negative consumer sentiment. General Motors lowers adjusted EPS forecast, citing significant tariff-related impact.",
    "url": "https://finnhub.io/api/news?id=4b918ccf3126a948e47b89078c6c11c89cd73104e3413c7cc58dabc613f73759",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746107280,
      "headline": "Wall Street Lunch: Big Macs Vs. Uncertainty",
      "id": 134175526,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195489700/image_2195489700.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "McDonald's U.S. comp sales decline is the largest since 2020, due to negative consumer sentiment. General Motors lowers adjusted EPS forecast, citing significant tariff-related impact.",
      "url": "https://finnhub.io/api/news?id=4b918ccf3126a948e47b89078c6c11c89cd73104e3413c7cc58dabc613f73759"
    }
  },
  {
    "ts": null,
    "headline": "Here's What Key Metrics Tell Us About Lilly (LLY) Q1 Earnings",
    "summary": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=bf346237579f098fbdfff27f3be940dae1008b63eaae267da5b215c9957218b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746106236,
      "headline": "Here's What Key Metrics Tell Us About Lilly (LLY) Q1 Earnings",
      "id": 134173469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=bf346237579f098fbdfff27f3be940dae1008b63eaae267da5b215c9957218b8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Lowers 2025 Earnings Outlook Despite Stronger-Than-Expected First-Quarter Results",
    "summary": "Eli Lilly (LLY) slashed its full-year earnings outlook on Thursday due to acquisition-related charge",
    "url": "https://finnhub.io/api/news?id=28ec7b3025410c528a42af720672657fb196977952a578894fedb125f4fd0966",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746104812,
      "headline": "Eli Lilly Lowers 2025 Earnings Outlook Despite Stronger-Than-Expected First-Quarter Results",
      "id": 134173470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) slashed its full-year earnings outlook on Thursday due to acquisition-related charge",
      "url": "https://finnhub.io/api/news?id=28ec7b3025410c528a42af720672657fb196977952a578894fedb125f4fd0966"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance",
    "summary": "Eli Lilly reported first quarter earnings on Thursday.",
    "url": "https://finnhub.io/api/news?id=57777f565dfc2c8fb091134cef17cb16e524506b08a80d3292f275a385ae3d12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746104088,
      "headline": "Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance",
      "id": 134173471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly reported first quarter earnings on Thursday.",
      "url": "https://finnhub.io/api/news?id=57777f565dfc2c8fb091134cef17cb16e524506b08a80d3292f275a385ae3d12"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVS",
    "summary": "Eli Lilly topped expectations Thursday, but shares tumbled after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug.",
    "url": "https://finnhub.io/api/news?id=906ad41d6e51c2d33867ddbd471a2707f2560de32eeded74acff8dd29b10b3f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746103971,
      "headline": "Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVS",
      "id": 134173472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly topped expectations Thursday, but shares tumbled after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug.",
      "url": "https://finnhub.io/api/news?id=906ad41d6e51c2d33867ddbd471a2707f2560de32eeded74acff8dd29b10b3f5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge",
    "summary": "Eli Lilly on Thursdaydownplayed CVS Health's decision to drop the company'sobesity drug Zepbound from some lists of medicines it covers forreimbursement, but shares of the drugmaker still fell more...",
    "url": "https://finnhub.io/api/news?id=39eeebcd4d39afff34ca5a120df16de600637379aa963bf31c32c9187b79becb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746101873,
      "headline": "Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge",
      "id": 134172932,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly on Thursdaydownplayed CVS Health's decision to drop the company'sobesity drug Zepbound from some lists of medicines it covers forreimbursement, but shares of the drugmaker still fell more...",
      "url": "https://finnhub.io/api/news?id=39eeebcd4d39afff34ca5a120df16de600637379aa963bf31c32c9187b79becb"
    }
  },
  {
    "ts": null,
    "headline": "If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?",
    "summary": "Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?",
    "url": "https://finnhub.io/api/news?id=428e26366024350974a7d1d16d126d7877e66c039154a1179f8515fe5d3cee4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100844,
      "headline": "If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?",
      "id": 134173473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?",
      "url": "https://finnhub.io/api/news?id=428e26366024350974a7d1d16d126d7877e66c039154a1179f8515fe5d3cee4d"
    }
  },
  {
    "ts": null,
    "headline": "Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly",
    "summary": "Eli Lilly Chief Executive David Ricks said manufacturing of certain drugs could come back to the U.S. if there is an economic incentive, such as lower tax rates for domestic production.  \"Particularly as the president says, 15% for domestic production would be one of the best in the world.\"",
    "url": "https://finnhub.io/api/news?id=20760950635cf51978c9de45cd8dc18ad36430c9df82886c6333f263f503305a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100805,
      "headline": "Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly",
      "id": 134173474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Chief Executive David Ricks said manufacturing of certain drugs could come back to the U.S. if there is an economic incentive, such as lower tax rates for domestic production.  \"Particularly as the president says, 15% for domestic production would be one of the best in the world.\"",
      "url": "https://finnhub.io/api/news?id=20760950635cf51978c9de45cd8dc18ad36430c9df82886c6333f263f503305a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Q1 Earnings Lag Estimates",
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=9c82f05602082e40e06383c8dbcaf3731b7176d124103702c8cfc9a5bd601557",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100506,
      "headline": "Eli Lilly (LLY) Q1 Earnings Lag Estimates",
      "id": 134173475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=9c82f05602082e40e06383c8dbcaf3731b7176d124103702c8cfc9a5bd601557"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Pre-Launch Inventories Capitalized As Of March 31, 2025 $601.4 Million, Primarily Related To Orforglipron - Filing",
    "summary": "Eli Lilly and Co: * ELI LILLY: PRE-LAUNCH INVENTORIES CAPITALIZED AS OF MARCH31,2025 $601.4 MILLION, PRIMARILY RELATED TO ORFORGLIPRONFurther company coverage: ...",
    "url": "https://finnhub.io/api/news?id=6482558b312fc43e297970f1e626bca8f708c5c4293ee653d86e28f3549d0e73",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100426,
      "headline": "Eli Lilly Reports Pre-Launch Inventories Capitalized As Of March 31, 2025 $601.4 Million, Primarily Related To Orforglipron - Filing",
      "id": 134172816,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * ELI LILLY: PRE-LAUNCH INVENTORIES CAPITALIZED AS OF MARCH31,2025 $601.4 MILLION, PRIMARILY RELATED TO ORFORGLIPRONFurther company coverage: ...",
      "url": "https://finnhub.io/api/news?id=6482558b312fc43e297970f1e626bca8f708c5c4293ee653d86e28f3549d0e73"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Beats Q1 Sales Targets",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=79d7daeeab438987f96af88d46298b8b6388dbd14bd04a600824216ac4840394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100099,
      "headline": "Eli Lilly (NYSE:LLY) Beats Q1 Sales Targets",
      "id": 134173476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=79d7daeeab438987f96af88d46298b8b6388dbd14bd04a600824216ac4840394"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds",
    "summary": "Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.",
    "url": "https://finnhub.io/api/news?id=07a6e082a7f016389f82c771647107e0fb54653f0370d3fc15bb3f389c33a49f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099900,
      "headline": "Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds",
      "id": 134173477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.",
      "url": "https://finnhub.io/api/news?id=07a6e082a7f016389f82c771647107e0fb54653f0370d3fc15bb3f389c33a49f"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drugs lead first-quarter profit surge at Eli Lilly",
    "summary": "Weight-loss drugs lead first-quarter profit surge at Eli Lilly",
    "url": "https://finnhub.io/api/news?id=e24a3394dc792624bcd4b49fbd1e733ed2f95fc2725fcbd9d746c7d38cb988ca",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099624,
      "headline": "Weight-loss drugs lead first-quarter profit surge at Eli Lilly",
      "id": 134171418,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e24a3394dc792624bcd4b49fbd1e733ed2f95fc2725fcbd9d746c7d38cb988ca"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Drops as Lowered Profit Outlook Outweighs Solid Q1 Results",
    "summary": "Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.",
    "url": "https://finnhub.io/api/news?id=5c8fb5f064d3bb70425a249b0fb7d292e6f03b452f53de61708421d84cd90451",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746097822,
      "headline": "Eli Lilly Stock Drops as Lowered Profit Outlook Outweighs Solid Q1 Results",
      "id": 134173478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.",
      "url": "https://finnhub.io/api/news?id=5c8fb5f064d3bb70425a249b0fb7d292e6f03b452f53de61708421d84cd90451"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Exec Says Tariffs Currently In Effect Do Not Materially Change 2025 Financial Outlook",
    "summary": "Eli Lilly and Co: * ELI LILLY EXEC SAYS ANNOUNCED TARIFFS CURRENTLY IN EFFECTDO NOTMATERIALLY CHANGE CO'S 2025 FINANCIAL OUTLOOK - CONF CALL * LILLY EXEC SAYS EXPANSION...",
    "url": "https://finnhub.io/api/news?id=7540acc9667c5314fb29d654f1f4447b9f2a35180e2542d8ca4f94a51cbc27d1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746097766,
      "headline": "Lilly Exec Says Tariffs Currently In Effect Do Not Materially Change 2025 Financial Outlook",
      "id": 134172546,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * ELI LILLY EXEC SAYS ANNOUNCED TARIFFS CURRENTLY IN EFFECTDO NOTMATERIALLY CHANGE CO'S 2025 FINANCIAL OUTLOOK - CONF CALL * LILLY EXEC SAYS EXPANSION...",
      "url": "https://finnhub.io/api/news?id=7540acc9667c5314fb29d654f1f4447b9f2a35180e2542d8ca4f94a51cbc27d1"
    }
  },
  {
    "ts": null,
    "headline": "WHO to back use of weight-loss drugs for adults globally, raises cost issue",
    "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday showed, marking a shift in its...",
    "url": "https://finnhub.io/api/news?id=6e7e9cd7ddb84486415b55f9a14464120c57a38c143a3925c1008c0fb21c5a9d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746097224,
      "headline": "WHO to back use of weight-loss drugs for adults globally, raises cost issue",
      "id": 134172485,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday showed, marking a shift in its...",
      "url": "https://finnhub.io/api/news?id=6e7e9cd7ddb84486415b55f9a14464120c57a38c143a3925c1008c0fb21c5a9d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly: Q1 Earnings Snapshot",
    "summary": "Earnings, adjusted for one-time gains and costs, came to $3.34 per share. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $3.52 per share.",
    "url": "https://finnhub.io/api/news?id=98f2ed0fad3529b4ed37b85fb55695bad2038b436dc673f72cfca46a719da766",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746097097,
      "headline": "Lilly: Q1 Earnings Snapshot",
      "id": 134173479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings, adjusted for one-time gains and costs, came to $3.34 per share. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $3.52 per share.",
      "url": "https://finnhub.io/api/news?id=98f2ed0fad3529b4ed37b85fb55695bad2038b436dc673f72cfca46a719da766"
    }
  },
  {
    "ts": null,
    "headline": "Lilly reports first-quarter 2025 financial results and highlights pipeline momentum",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=e25c8afa78dd1f3ddecda3f56584ee9136c9638c3e3f80bee14f5e10db8eecb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746096300,
      "headline": "Lilly reports first-quarter 2025 financial results and highlights pipeline momentum",
      "id": 134173481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=e25c8afa78dd1f3ddecda3f56584ee9136c9638c3e3f80bee14f5e10db8eecb2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats",
    "summary": "Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats",
    "url": "https://finnhub.io/api/news?id=649bc731072bd1f509032159788f6ff01fa60993d41a31e8001f1b93f3bfdea7",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746089571,
      "headline": "Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats",
      "id": 134179427,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats",
      "url": "https://finnhub.io/api/news?id=649bc731072bd1f509032159788f6ff01fa60993d41a31e8001f1b93f3bfdea7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's strong quarter undercut by CVS move to drop Zepbound coverage",
    "summary": "Eli Lilly on Thursday postedbetter-than-expected quarterly results, but CVS Health'sdecision to drop the company's obesity drug Zepbound from thelist of medicines it covers for reimbursement...",
    "url": "https://finnhub.io/api/news?id=d0c2be7330c47879d3b8576e6a14327806c7e172dac92a832e09b93faf863be2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746089469,
      "headline": "Eli Lilly's strong quarter undercut by CVS move to drop Zepbound coverage",
      "id": 134171566,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly on Thursday postedbetter-than-expected quarterly results, but CVS Health'sdecision to drop the company's obesity drug Zepbound from thelist of medicines it covers for reimbursement...",
      "url": "https://finnhub.io/api/news?id=d0c2be7330c47879d3b8576e6a14327806c7e172dac92a832e09b93faf863be2"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise As Microsoft, Meta Jump; Tesla Chair Denies Elon Musk Report",
    "summary": "Dow Jones Futures Rise As Microsoft, Meta Jump; Tesla Chair Denies Elon Musk Report",
    "url": "https://finnhub.io/api/news?id=ed605c3094ef350a41b53ca97136c4bd474ae3c3268b1c0192d52cf164f544d6",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746087256,
      "headline": "Dow Jones Futures Rise As Microsoft, Meta Jump; Tesla Chair Denies Elon Musk Report",
      "id": 134179069,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Dow Jones Futures Rise As Microsoft, Meta Jump; Tesla Chair Denies Elon Musk Report",
      "url": "https://finnhub.io/api/news?id=ed605c3094ef350a41b53ca97136c4bd474ae3c3268b1c0192d52cf164f544d6"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health’s Aetna to exit Obamacare business, boost Wegovy access",
    "summary": "CVS Health’s Aetna to exit Obamacare business, boost Wegovy access",
    "url": "https://finnhub.io/api/news?id=2bbffbd3ba17446df89b09f1bc82cbd7312a1209bd2117ed796c36c2ca2c4341",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746087000,
      "headline": "CVS Health’s Aetna to exit Obamacare business, boost Wegovy access",
      "id": 134179449,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "CVS Health’s Aetna to exit Obamacare business, boost Wegovy access",
      "url": "https://finnhub.io/api/news?id=2bbffbd3ba17446df89b09f1bc82cbd7312a1209bd2117ed796c36c2ca2c4341"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's weight-loss drug sales miss expectations, shares fall",
    "summary": "May 1 - Eli Lilly on Thursday posted better-than-expectedquarterly results, although sales of its popular weight-lossdrug, Zepbound, came in slightly below Wall Street...",
    "url": "https://finnhub.io/api/news?id=dea3539a9f74a91c3107aeac3d4166358b94f58b6fee54d75289fcf80e6d968c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746084409,
      "headline": "Eli Lilly's weight-loss drug sales miss expectations, shares fall",
      "id": 134170788,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "May 1 - Eli Lilly on Thursday posted better-than-expectedquarterly results, although sales of its popular weight-lossdrug, Zepbound, came in slightly below Wall Street...",
      "url": "https://finnhub.io/api/news?id=dea3539a9f74a91c3107aeac3d4166358b94f58b6fee54d75289fcf80e6d968c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments",
    "summary": "By Denny Jacob Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion,...",
    "url": "https://finnhub.io/api/news?id=570cde2119ccf9b5cd00ddbc88aa1930e08ccbda41e337f9de9c200dfc3a4d51",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746084307,
      "headline": "Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments",
      "id": 134170779,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Denny Jacob Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion,...",
      "url": "https://finnhub.io/api/news?id=570cde2119ccf9b5cd00ddbc88aa1930e08ccbda41e337f9de9c200dfc3a4d51"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-WHO set to back use of weight-loss drugs for adults globally, raises cost issue",
    "summary": "LONDON -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a...",
    "url": "https://finnhub.io/api/news?id=8f211fbf82f0e2cbcbd8aab84cfa1d6e71537dac597e6dc54ddef5e66ece1c88",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082752,
      "headline": "Exclusive-WHO set to back use of weight-loss drugs for adults globally, raises cost issue",
      "id": 134170677,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "LONDON -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a...",
      "url": "https://finnhub.io/api/news?id=8f211fbf82f0e2cbcbd8aab84cfa1d6e71537dac597e6dc54ddef5e66ece1c88"
    }
  },
  {
    "ts": null,
    "headline": "WHO set to back use of weight-loss drugs for adults globally, raises cost issue",
    "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday shows, marking a shift in its...",
    "url": "https://finnhub.io/api/news?id=b51587c47e527aa794c2a72d09b8940fac7502c967f59b591ef0885091c9ef6f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082752,
      "headline": "WHO set to back use of weight-loss drugs for adults globally, raises cost issue",
      "id": 134170525,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday shows, marking a shift in its...",
      "url": "https://finnhub.io/api/news?id=b51587c47e527aa794c2a72d09b8940fac7502c967f59b591ef0885091c9ef6f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and : 2025 Earnings Presentation",
    "summary": "ELI LILLY AND COMPANY Q1 2025 EARNINGS CALL ...",
    "url": "https://finnhub.io/api/news?id=d67d0f98384afef6f596f3713cabbe450f46eee634c89c108979d21501939d1f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082746,
      "headline": "Eli Lilly and : 2025 Earnings Presentation",
      "id": 134170496,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "ELI LILLY AND COMPANY Q1 2025 EARNINGS CALL ...",
      "url": "https://finnhub.io/api/news?id=d67d0f98384afef6f596f3713cabbe450f46eee634c89c108979d21501939d1f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly posts strong Q1 results, but weight-loss drug sales disappoint",
    "summary": "May 1 - Eli Lilly on Thursday posted better-than-expectedfirst quarter revenue and profit, although sales of its popularweight-loss drug, Zepbound, came in slightly below Wall...",
    "url": "https://finnhub.io/api/news?id=3b5fa7ba023fe39d64264f57a472200209023a7f1444487d76daf3503926d5d8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082623,
      "headline": "Eli Lilly posts strong Q1 results, but weight-loss drug sales disappoint",
      "id": 134170484,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "May 1 - Eli Lilly on Thursday posted better-than-expectedfirst quarter revenue and profit, although sales of its popularweight-loss drug, Zepbound, came in slightly below Wall...",
      "url": "https://finnhub.io/api/news?id=3b5fa7ba023fe39d64264f57a472200209023a7f1444487d76daf3503926d5d8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly beats Q1 profit estimates on strength of diabetes drug",
    "summary": "Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an...",
    "url": "https://finnhub.io/api/news?id=5c18dfc35c65b0ae0b089485e81a0d6c2aa30ec9c286ce35b52dcb64c9385efb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082414,
      "headline": "Eli Lilly beats Q1 profit estimates on strength of diabetes drug",
      "id": 134170458,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an...",
      "url": "https://finnhub.io/api/news?id=5c18dfc35c65b0ae0b089485e81a0d6c2aa30ec9c286ce35b52dcb64c9385efb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and : 2025 Press Release",
    "summary": "‌May 1, 2025 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; 416-4363 Mike Czapar; czapar_michael_c@lilly.com; 617-0983 ...",
    "url": "https://finnhub.io/api/news?id=18f32cefb9e4e740293c56df8f17ee09df8beda5ee4adae352fea0f7dd704093",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746082148,
      "headline": "Eli Lilly and : 2025 Press Release",
      "id": 134170398,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "‌May 1, 2025 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; 416-4363 Mike Czapar; czapar_michael_c@lilly.com; 617-0983 ...",
      "url": "https://finnhub.io/api/news?id=18f32cefb9e4e740293c56df8f17ee09df8beda5ee4adae352fea0f7dd704093"
    }
  },
  {
    "ts": null,
    "headline": "Apple and Amazon.com headline earnings",
    "summary": "Apple and Amazon.com headline earnings",
    "url": "https://finnhub.io/api/news?id=aea36bfd24e1ade1e34f0b905e1e464d4c9742dc5ed129a787a8b2a2b35c2ef2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746077102,
      "headline": "Apple and Amazon.com headline earnings",
      "id": 134179451,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Apple and Amazon.com headline earnings",
      "url": "https://finnhub.io/api/news?id=aea36bfd24e1ade1e34f0b905e1e464d4c9742dc5ed129a787a8b2a2b35c2ef2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Fear Is Overblown",
    "summary": "Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline and my recommendation of NVO stock.",
    "url": "https://finnhub.io/api/news?id=55a27180d31ee9a499a37eff4b958f81c06ac57862be1c03f56a329ff72c0d49",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746066271,
      "headline": "Novo Nordisk: The Fear Is Overblown",
      "id": 134168977,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2171515418/image_2171515418.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline and my recommendation of NVO stock.",
      "url": "https://finnhub.io/api/news?id=55a27180d31ee9a499a37eff4b958f81c06ac57862be1c03f56a329ff72c0d49"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): Jim Cramer Rides the GLP-1 Wave — “Hundreds of Thousands Are Filling Scripts Weekly”",
    "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Eli Lilly and Compnay (NYSE:LLY) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence […]",
    "url": "https://finnhub.io/api/news?id=f4471ba0aa0ea011c7b820f76b82a18d26a06525f8a90d2682158b8a7c51262e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746057770,
      "headline": "Eli Lilly and Company (LLY): Jim Cramer Rides the GLP-1 Wave — “Hundreds of Thousands Are Filling Scripts Weekly”",
      "id": 134165858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Eli Lilly and Compnay (NYSE:LLY) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence […]",
      "url": "https://finnhub.io/api/news?id=f4471ba0aa0ea011c7b820f76b82a18d26a06525f8a90d2682158b8a7c51262e"
    }
  }
]